<b>Methods</b>: A retrospective study was conducted utilizing pathological samples from lung cancer patients harboring mutations in <i>EGFR</i>, <i>KRAS</i>, <i>ALK</i>, <i>BRAF</i>, <i>MET</i>, <i>HER2</i>, <i>ROS1</i>, <i>NTRK</i>, and <i>NRG1</i>. This evidence concerns the gene KRAS and lung carcinoma.